Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

Antibody Structure and Classes

Antibody Structure and Classes

Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.

Antibody Actions

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...

Antibody Structure

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...

Humoral Immune Responses

Humoral Immune Responses

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Engineering and Partial Characterization of an Anti-IL-23/Anti-TNF-α Bispecific Domain Antibody Fused to Human Serum Albumin Domain for Inflammatory Disease Therapy.

Applied biochemistry and biotechnology·2026

Same author

The rise of bispecific T-cell engager (BsTCE) antibodies: a potentially game-changing approach for breast cancer therapy?

Drug discovery today·2026

Same author

Development and partial characterization of fused human endostatin.

Protein expression and purification·2026

Same author

Correction: Photosensitizer-Antibody Conjugates (PhotoBodies): Emerging Frontiers in the Field of Theranostics.

Pharmaceutical research·2026

Same author

Radioligand-Antibody Conjugates: Integrating Antibody Engineering, Chelator Chemistry, and Radioligands for Precision Theranosis.

Molecular diagnosis & therapy·2025

Same author

PolyBodies for the Treatment of Respiratory Syncytial Virus Infection.

Drug discovery today·2025

Search research articles

Related Experiment Video

Updated: Jun 11, 2025

Laboratory Scale Production and Purification of a Therapeutic Antibody

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Polybodies: Next-generation clinical antibodies.

Abhay H Pande¹, Sandeep¹, Suraj H Shinde¹

¹Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Mohali 160062, Punjab, India.

Drug Discovery Today

|October 6, 2024

Summary

Next-generation polybodies offer significant improvements over conventional antibodies. These engineered proteins can target multiple antigens simultaneously, leading to more effective and customizable immunotherapies.

Keywords:

antibody engineering conventional antibody polyspecificity polyvalency single-domain antibody

More Related Videos

Construction of Synthetic Phage Displayed Fab Library with Tailored Diversity

Construction of Synthetic Phage Displayed Fab Library with Tailored Diversity

Published on: May 1, 2018

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Related Experiment Videos

Last Updated: Jun 11, 2025

Laboratory Scale Production and Purification of a Therapeutic Antibody

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Construction of Synthetic Phage Displayed Fab Library with Tailored Diversity

Construction of Synthetic Phage Displayed Fab Library with Tailored Diversity

Published on: May 1, 2018

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Area of Science:

Biotechnology
Immunology
Protein Engineering

Background:

Conventional antibodies, including fragments like F(ab')2, Fab, scFv, and VHH, are monospecific and have historically dominated biopharmaceuticals.
Protein engineering has advanced antibody technology, leading to the development of next-generation polybodies.

Purpose of the Study:

To review recent developments in polybodies.
To highlight the advantages of polybodies over conventional antibodies.
To discuss future perspectives for innovative immunotherapies using polybodies.

Main Methods:

Review of scientific literature on polybody development and applications.
Comparative analysis of polybodies and conventional antibodies based on efficacy, specificity, and resilience.
Exploration of protein engineering strategies for polybody design.

Main Results:

Polybodies are engineered antibodies that can target multiple antigens simultaneously, offering polyspecificity and/or polyvalency.
Polybodies demonstrate superiority over conventional antibodies, exhibiting enhanced efficacy, broader spectrum activity, and improved resistance resilience.
Polybodies present a customizable and cost-effective solution for healthcare.

Conclusions:

Polybodies represent a significant advancement over conventional antibodies due to their multi-targeting capabilities.
Further development of polybodies holds promise for creating innovative and more effective immunotherapies.
The review encourages continued research and development in polybody technology for future therapeutic applications.